GLIPR1L1 Antibody
| Code | Size | Price |
|---|
| PSI-7625-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-7625-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Western Blot (WB)
Documents
Further Information
Additional Names:
GLIPR1L1 Antibody: PRO7434, ALKN2972, GLIPR1-like protein 1
Application Note:
GLIPR1L1 antibody can be used for detection of GLIPR1L1 by Western blot at 1 - 2 μg/ml. Antibody can also be used for Immunohistochemistry starting at 5 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Background:
The GLIPR1-like 1 protein (GLIPR1L1) gene is part of a p53 target gene cluster that includes the related proteins GLIPR1 and GLIPR1L2 (1). GLIPR1L1 is similar to both the pathogenesis-related protein (PR) superfamily and the cysteine-rich secretory protein (CRISP) family (2). GLIPR1 is a tumor suppressor whose expression is regulated by p53 (3). Unlike GLIPR1, GLIPR1L1 is expressed primarily in the testis and is thought to be involved in the binding of sperm to the oocyte complex (4).
Background References:
- Ren C, Ren CH, Li L, et al. Identification and characterization of RTVP1/GLIPR1-like genes, a novel p53 target gene cluster. Genomics 2006; 88:163-72.
- Murphy EV, Zhang Y, Zhu W, et al. The human glioma pathogenesis-related protein is structurally related to pathogenesis-related proteins and its gene is expressed specifically in brain tumors. Gene 1995; 159:131-5.
- Ren C, Li L, Yang G, et al. RTVP-1, a tumor suppressor inactivated by methylation in prostate cancer. Cancer Res. 2004; 64:969-76.
- Gibbs GM, Lo JC, Nixon B, et al. Glioma pathogenesis-related 1-like 1 is testis enriched, dynamically modified, and redistributed during male germ cell maturation and has a potential role in sperm-oocyte binding. Endocrinology 2010; 151:2332-42.
Buffer:
GLIPR1L1 antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
GLIPR1L1 antibody was raised against an 18 amino acid peptide near the amino terminus of human GLIPR1L1 .
The immunogen is located within amino acids 20 - 70 of GLIPR1L1.
The immunogen is located within amino acids 20 - 70 of GLIPR1L1.
NCBI Gene ID #:
256710
NCBI Official Name:
GLI pathogenesis-related 1 like 1
NCBI Official Symbol:
GLIPR1L1
NCBI Organism:
homo sapiens
Physical State:
Liquid
PREDICTED MOLECULAR WEIGHT:
Predicted: 26 kDa
Observed: 23 kDa
Observed: 23 kDa
Protein Accession #:
NP_689992
Protein GI Number:
22749527
Purification:
GLIPR1L1 antibody is affinity chromatography purified via peptide column.
Research Area:
Homeostasis
SPECIFICITY:
GLIPR1L1 antibody is human specific. At least two isoforms of GLIPR1L1 are known to exist; this antibody will detect both isoforms. This antibody is predicted to not cross-react with other GLIPR or GLIPR-like proteins.
Swissprot #:
Q6UWM5
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | GLIPR1L1 Peptide | PSI-7625P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|